Skip to content
10-K

Annual Report

Coherus Oncology, Inc. CHRS

0001104659-26-025308

← back to feed
Filed
Mar 9, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 28, 2026 149.89M sh
Shares Diluted FY 2025 · Dec 31, 2025 117.14M sh
Shares Diluted restated FY 2025 · Dec 31, 2024 114.55M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$138.51M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$20.44M
Cash And Equivalents FY 2025 · Dec 31, 2025 $88.88M
Cash And Equivalents FY 2025 · Dec 31, 2024 $125.99M
Stockholders Equity FY 2025 · Dec 31, 2025 $61.01M
Stockholders Equity FY 2025 · Dec 31, 2024 −$131.99M
Stockholders Equity FY 2025 · Dec 31, 2023 −$193.43M
Current Liabilities FY 2025 · Dec 31, 2025 $140.39M
Current Liabilities FY 2025 · Dec 31, 2024 $282.98M
Total Liabilities FY 2025 · Dec 31, 2025 $197.33M
Total Liabilities FY 2025 · Dec 31, 2024 $580.52M
Current Assets FY 2025 · Dec 31, 2025 $206.71M
Current Assets FY 2025 · Dec 31, 2024 $341.58M
Total Assets FY 2025 · Dec 31, 2025 $258.34M
Total Assets FY 2025 · Dec 31, 2024 $448.53M
Eps Diluted FY 2025 · Dec 31, 2025 $1.43
Eps Diluted FY 2025 · Dec 31, 2024 $0.25
Eps Basic FY 2025 · Dec 31, 2025 $1.43
Eps Basic FY 2025 · Dec 31, 2024 $0.25
Sga Expense FY 2025 · Dec 31, 2025 $100.6M
Sga Expense restated FY 2025 · Dec 31, 2024 $125.48M
Rd Expense FY 2025 · Dec 31, 2025 $108.89M
Rd Expense restated FY 2025 · Dec 31, 2024 $91.83M
Net Income FY 2025 · Dec 31, 2025 $168.02M
Net Income FY 2025 · Dec 31, 2024 $28.51M
Operating Income FY 2025 · Dec 31, 2025 −$181.13M
Operating Income restated FY 2025 · Dec 31, 2024 −$199.65M
Cost Of Revenue FY 2025 · Dec 31, 2025 $13.81M
Cost Of Revenue restated FY 2025 · Dec 31, 2024 $8.73M